Located Globally

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets.  Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to increase targeted delivery, minimize reflux and reduce damage to healthy tissue.

 

Surefire Medical’s vision is to improve patients’ lives by delivering
a new standard of excellence for Interventional Radiology.

  • Surefire Board of Directors

    • Norman Weldon

      Chairman

      Dr. Weldon is a highly experienced medical device leader with a track record of success at the highest business and operational levels. Dr. Weldon’s background is in economics, technology and general management. He has been the CEO of three public companies: CTS Corporation (NYSE CTS), Cordis Corporation (NASDAQ CORD) and Corvita Corporation (NASDAQ CVTA). He was a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation, Enable Medical Corporation, AtriCure, Inc., Medivance, Inc. and Neuronetics, Inc. As the Chairman of the Board, Dr. Weldon provides key guidance in all aspects of the company, sharing his wealth of knowledge, experience, and network of talent.

    • James E. Chomas, PhD

      Director

      Dr. Chomas received his Bachelor’s of Science in Engineering from Duke University and completed doctoral training at the University of Virginia, investigating the use of ultrasound in breast cancer characterization. He has 12 years experience in developing devices from initial concept through pre-clinical trials and clinical trials, and he has authored 17 patents in medical devices. In five years with Siemens Ultrasound as Senior Engineering Manager, Dr. Chomas led a team of engineers and released six product features. Most recently, Dr. Chomas was the Director of Research at Cabochon, where he led the engineering team in the research, development and pre-clinical testing, which ultimately culminated in a 35-patient clinical trial.

    • Ginger L. Graham

      Director

      Ginger Graham is a recognized biopharmaceutical and medical device leader with more than 30 years experience. She teaches a course in entrepreneurship at the Harvard Business School and consults to first-time CEO’s in the areas of leadership, strategy, board-effectiveness, and organization-building.

      Ms. Graham is the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on diabetes and obesity. Prior to her time at Amylin, she was Group Chairman, Office of the President for Guidant Corporation, a major cardiovascular medical device manufacturer based in Indianapolis, IN. She started her career in healthcare at Eli Lilly and Company in a variety of roles.

      Ms. Graham serves on the Boards of Directors for Walgreen Co., Genomic Health, Inc., Proteus Biomedical, Surefire Medical, and the American Diabetes Association Research Foundation, where she serves as Vice Chair. Ms. Graham received a Bachelor of Science degree in agricultural economics from the University of Arkansas, and holds an MBA degree, with distinction, from Harvard University.

    • Karen Cassidy

      Director

      Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna’s Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

    • Mark Lupa

      Director

      Dr. Lupa holds a Bachelor’s of Science degree from Northwestern University, a Master’s degree from the University of Sussex (England) in Biomedical Engineering and completed his doctoral program in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for 15 years at institutions worldwide, including the University of Colorado and the University of California San Francisco. Dr. Lupa’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to the private investment company Tango to focus on technology and Life Science investments. He is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs. Dr. Lupa also served as CFO of Taligen from inception of the company in 2004 until early 2008.

    • Gene McGrevin

      Director

      With more than 25 years of experience in the medical industry, Gene McGrevin has held senior management positions in global companies including Johnson & Johnson and Kimberly-Clark Corporation. Mr. McGrevin also was instrumental in the expansion and sale of several medical startups.  They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard).  In addition, Mr. McGrevin serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics. Mr. McGrevin holds an MBA from the University of Pennsylvania’s Wharton School.  He earned a BA in economics at the University of Pittsburgh.

    • Beverly Huss, MS

      Director

      Beverly Huss, currently President and CEO of Qool Therapeutics, has more than 30 years of experience in the medical industry. Prior to joining Qool, Ms. Huss was President and CEO of Vibrynt, Inc., a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity.  While at Guidant for more than 19 years, Ms. Huss fulfilled a variety of executive roles within the company’s various medical device divisions, including serving as President of the worldwide Endovascular Solutions business where worldwide revenues quadrupled to $150 million for the carotid and peripheral vascular business in four years. In addition, Ms. Huss built Guidant’s coronary stent business, the market leader for 27 of 28 quarters.

      Earlier in her career, Ms. Huss held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel.  Additionally, she served as chair of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA- based cell therapy company.  Ms. Huss holds an M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois.  She has several patents to her credit in the cardiovascular and obesity medical device areas.

  • Surefire Management Team

    • James E. Chomas, PhD

      Founder and CEO

      Dr. Chomas received his Bachelor’s of Science in Engineering from Duke University and completed doctoral training at the University of Virginia, investigating the use of ultrasound in breast cancer characterization. He has 12 years experience in developing devices from initial concept through pre-clinical trials and clinical trials, and he has authored 17 patents in medical devices. In five years with Siemens Ultrasound as Senior Engineering Manager, Dr. Chomas led a team of engineers and released six product features. Most recently, Dr. Chomas was the Director of Research at Cabochon, where he led the engineering team in the research, development and pre-clinical testing, which ultimately culminated in a 35-patient clinical trial.

    • Aravind Arepally, MD, FSIR

      Founder

      Dr. Arepally has extensive expertise with both the clinical and research aspect of embolotherapy. Having 10 years of experience in clinical interventional radiology, he has performed more than 500 embolotherapy cases while on faculty at Johns Hopkins Medical Institutes. In addition, Dr. Arepally has led a research lab at JHU focused on the development of embolic beads for targeted delivery, and is currently in clinical practice at Piedmont Hospital. Dr. Arepally provides a critical link for the clinical and technical needs and demands of a microcatheter.

      Dr. Arepally obtained his mathematics degree from Mercer University. He went on to obtain his MD at Emory University School of Medicine and continued residency and chief residency in Radiology at Emory University Hospital. He went to Johns Hopkins for additional training in Interventional Radiology and joined the faculty in 2000. From 2007 to 2009, Aravind was the Clinical Director for the Center for Bioengineering Innovation and Design, with a research focus on the development of targeted drug and cellular delivery to treat diabetes and obesity. He has authored more than 150 papers, books, and abstracts, and has been a principal investigator or co-investigator on more than 15 grants (5 NIH). Dr. Arepally is the recipient of numerous national awards and grants for his research in the field of MRI and device development.

    • Robert Holburn

      CFO

      Robert Holburn, Jr. has more than 35 years in senior financial management positions in private and public technology companies. For the last 10 years he held the position of Vice President and CFO of Medivance, Inc., a medical device manufacturer. Prior to joining the Surefire Medical team, Mr. Holburn also served as President, Chief Operating Officer of IPSeal, a venture capital backed telecommunications company; Vice President, CFO of Solant, Inc.; Vice President, CFO of Rogue Wave Software. He has extensive tenures with Advanced Power Technology and Texas Instruments. Mr. Holburn holds an MBA from The College of William and Mary and a Bachelors of Science degree from the University of Rhode Island and was a commissioned officer in the United States Army.

    • Stephen Cambridge

      Vice President of Sales & Marketing

      Mr. Cambridge brings 25 years of experience in sales, training, recruiting, management and marketing in the pharmaceutical and medical device markets for both large and start-up companies. Mr. Cambridge has deep medical device sales experience with winning organizations such as Cordis Corporation, DVI, Inc., Cook, Inc., AVE, Inc., and AtriCure, Inc. As Director of Sales for AtriCure, Inc., Mr. Cambridge built a 20-person sales team who achieved $20 million in revenue in the company’s first two years. Two years later, as Vice President of Sales for AtriCure, Inc., Mr. Cambridge led a team of 40 sales representatives to achieve yearly revenue sales of $39 million. Mr. Cambridge has been a member of three successful start-up companies that were either acquired or went public. Possessing a passion for teamwork, he is highly experienced in building a dedicated, motivated, and results-driven sales force.

    • Lori Ann Santamaria

      Vice President of Operations

      Ms. Santamaria has experience bringing multiple products to market from concept through commercialization including initial prototyping, pre-clinical testing and design validation. She began her career at Cordis Neurovascular, part of Johnson and Johnson. During her tenure there she held positions in research and development, production and marketing. She led the development of microcatheters for both the neurovascular and peripheral markets. She subsequently managed the global product launch, including training the sales force in the U.S., Latin America, Europe and Asia. Most recently she was the Director of Product Development for OrbusNeich Medical, Inc., where she was responsible for the commercialization of a combination stent platform which required a 180 patient randomized clinical trial. There Ms. Santamaria also led the development and transfer of manufacturing process to plants outside the U.S. Ms. Santamaria received her undergraduate degree from the University of Florida and is currently pursuing her MBA with a specialization in Health Sector Management and Policy from the University of Miami.

    • Rebecca Offner

      Director of Clinical Affairs

      Rebecca (Donzanti) Offner has been in the medical device industry for 27 years. She has worked in clinical services, sales, clinical personnel management, product development, product clinical validation and clinical research monitoring. Ms. Offner has excelled in bringing innovative technology from the bench to active clinical use. She most recently came from Medivance/Bard where she worked closely with engineering during product development and successfully introduced new technology to national and international clinical experts. Her market development skills led to tremendous growth in both the domestic and international markets. She graduated from Widener University and received her Master’s degree from the University of Pennsylvania.

    • Christopher Mennone

      Director of International Business

      Mr. Mennone has spent more than 30 years in the international medical device industry building international sales and marketing organizations. His contacts and relationships with hundreds of physicians, business partners and international distributors give Surefire Medical an advantage in rapidly establishing an international presence. Mr. Mennone built highly successful sales and marketing organizations using the direct sales model in as many as 17 markets and the distributor channel in another 80.

    • Lynne Aronson

      Vice President of Regulatory and Quality

      Ms. Aronson has 25 years of experience in the medical device industry, focusing on domestic and international regulatory affairs, quality assurance and clinical research in temperature management, interventional cardiology, hemodialysis and orthopedics. For the past 11 years, Ms. Aronson was the Director of RA/QA at Medivance, Inc. (C.R. Bard). Additionally, she has held positions at Global Therapeutics (Cook), COBE Renal Care (Gambro), Acufex Microsurgical (Smith & Nephew), Medical Device Consultants, Inc., and Duke University Medical Center. Ms. Aronson received a Bachelor’s of Science in Biomedical Engineering from Duke University.

    • Karen Cassidy

      VP of Business Development

      Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna’s Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

    • Riley Kyle

      Controller

      Mr. Kyle has more than 30 years of experience in financial and management positions in the medical device, technology and transportation industries. Focusing in the areas of general ledger control, budgeting, cash management, financial reporting, systems and process improvements, he served as Controller at Medivance, Accounting Services Manager for Rogue Wave, and Accounting Operation Manager for Ryder Transportation. Mr. Kyle received his bachelor’s degree from University of Colorado at Boulder.
  • Surefire Scientific Advisory Board

    • Aravind Arepally, MD, FSIR

      Chairman, Piedmont Hospital

      Dr. Arepally has extensive expertise with both the clinical and research aspect of embolotherapy. Having 10 years of experience in clinical interventional radiology, he has performed more than 500 embolotherapy cases while on faculty at Johns Hopkins Medical Institutes. In addition, Dr. Arepally has led a research lab at JHU focused on the development of embolic beads for targeted delivery, and is currently in clinical practice at Piedmont Hospital. Dr. Arepally provides a critical link for the clinical and technical needs and demands of a microcatheter.

      Dr. Arepally obtained his mathematics degree from Mercer University. He went on to obtain his MD at Emory University School of Medicine and continued residency and chief residency in Radiology at Emory University Hospital. He went to Johns Hopkins for additional training in Interventional Radiology and joined the faculty in 2000. From 2007 to 2009, Aravind was the Clinical Director for the Center for Bioengineering Innovation and Design, with a research focus on the development of targeted drug and cellular delivery to treat diabetes and obesity. He has authored more than 150 papers, books, and abstracts, and has been a principal investigator or co-investigator on more than 15 grants (5 NIH). Dr. Arepally is the recipient of numerous national awards and grants for his research in the field of MRI and device development.

    • James Benenati, MD

      Baptist Cardiac and Vascular Institute

      Dr. Benenati joined Baptist Cardiac & Vascular Institute in 1990 and is currently the Medical Director of the Peripheral Vascular Laboratory. He is Clinical Associate Professor of Radiology at the University of South Florida College of Medicine and Program Director of the ACGME-accredited fellowship program in interventional radiology at the Institute.  He serves as a clinical professor of biomedical engineering at Florida International University, and he is the Medical Director a technologist sonography program at Nova Southeastern University.

      Dr. Benenati received his Bachelor’s Degree from the University of Notre Dame and his Medical Degree from the University of South Florida College of Medicine. He completed a residency in diagnostic radiology at Indiana University Medical Center and a fellowship in cardiovascular and interventional radiology at Johns Hopkins Medical School.

      Dr. Benenati is a Fellow of the Society of Cardiovascular & Interventional Radiology, a Fellow of the American Heart Association and a member of the Radiological Society of North America. He is the current President and a member of the Executive Council of the Society of Interventional Radiology.  Dr. Benenati is also the President of the Intersociety Commission for the Accreditation of Vascular Laboratories (ICAVL). He formerly served as the annual meeting chairman for the Society of Interventional Radiology.

    • Charles Nutting, DO

      Sky Ridge Medical Center

      Dr. Nutting completed his undergraduate education at Loyola University of Chicago and a D.O. from Chicago College of Osteopathic Medicine. He went on to complete his residency at Olympia Fields Hospital in Diagnostic Radiology, followed by a fellowship in Interventional Radiology at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. Dr. Nutting served as the Chief of Interventional Radiology at Good Samaritan Regional Medical Center and is currently the Chief of Interventional Radiology at Radiology Imaging Associates, and he performs procedures at Sky Ridge Medical Center and Swedish Medical Center in Colorado. Dr. Nutting has been a leading practitioner and clinical researcher in radioembolization, and through his leadership, Sky Ridge is a SirTex Center of Excellence for radioembolization procedures. Dr. Nutting is an active member of the Society of Interventional Radiologists, chairs the practice development subcommittee and is a proctor for SirTex radioembolization procedures throughout the U.S.

    • Leonard Pinchuk, PhD

      CEO, Innovia LLC

      Dr. Pinchuk is the Co-founder, President, and CEO of Innovia. As an inventor with a background in Chemistry, Engineering and Medicine, he initiates and oversees all projects, and also provides substantial product and process development input.

      Dr. Pinchuk is a world-renowned expert in the field of biomaterials and medical devices with more than 80 patents in this area. His accomplishments include the invention of the nylon angioplasty balloon, which has now become the world’s most popular angioplasty balloon, marketed by Cordis Corporation, Boston Scientific Corporation (“BSC”), and Guidant Corporation; a flexible coronary stent; the family of polycarbonate urethane biomaterials for implantation applications; and polyurethane-based vascular grafts and stent-grafts, including the first modular bifurcated stent-graft for treating abdominal aortic aneurysms. Dr. Pinchuk’s most notable achievement has been the development of a novel family of biocompatible elastomeric copolymers. Specific formulations of this polymer have enabled the next generation of coronary stents, namely the Boston Scientific Taxus® Stent, where drugs can be released from these devices to inhibit restenosis.

    • Daniel Sze, MD, PhD

      Stanford University Medical Center

      Dr. Sze completed his undergraduate education at Harvard double majoring in biochemistry and studio arts. After a brief stint as a graphic designer and medical illustrator, he went on to complete an MD and PhD in Biophysics at Stanford, internship at California Pacific Medical Center, and residency and chief residency in Radiology at UCSF. He returned to Stanford for additional training in Interventional Radiology and joined the faculty in 1997. His clinical and research interests include treatment of cancers using oncolytic viruses, radioembolization, chemoembolization, ablation, and other minimally-invasive methods. Other clinical research interests include treatment of aortic dissections and aneurysms, management of portal hypertension and cirrhosis, venous reconstruction and pulmonary embolism, organ transplant-related complications, and magnetic resonance-guided interventions. He received the Young Investigator Award from the Society of Interventional Radiology in 2002. He has authored more than 200 papers, books, and abstracts, and has been a principal investigator or co-investigator in more than 30 clinical trials.

    • Ryan N. Majoria, MD

      Our Lady of the Lake Regional Medical Center

      Dr. Majoria pursued a chemistry degree at the University of New Orleans in 1984 for his undergraduate education where he received academic and track and field scholarships, as well as the Rene and Glorain Scholarship for Cancer Research in 1986. He was accepted early into Louisiana State University Medical School in New Orleans during his third year of college in 1987, and decided to forego his college degree to pursue his medical career. After receiving his medical degree in 1991, Majoria completed his internship in Internal Medicine at the Alton Ochsner Medical Foundation in New Orleans in 1992 and pursued his diagnostic and interventional radiology residency at the University of South Alabama Medical Center in Mobile, Alabama. He received his Board Certification in 1996.

      Dr. Majoria then began his private practice career in Baton Rouge, Louisiana performing mostly interventional radiology at the largest non-charity hospital in the state at Our Lady of the Lake Regional Medical Center. In early 2000, he became Chief of Interventional Radiology and Interventional Oncology. With his early acceptance of newer minimally invasive techniques, such as arterial embolization and radiofrequency ablation, the interventional radiology practice grew exponentially.

    • Fred Moeslein, MD, PhD

      University of Maryland Medical Center

      Dr. Moeslein received his undergraduate degree in Biochemistry from Case Western Reserve University and his medical and doctoral degrees from Case Western Reserve University. He completed a residency in diagnostic radiology at The Cleveland Clinic and a fellowship in vascular and interventional radiology at The University of Maryland. After the completion of these residencies, Dr. Moeslein served as Assistant Professor of Radiology at the University of Pittsburgh, before returning to the University of Maryland School of Medicine. He currently serves as Interim Director, Division of Vascular and Interventional Radiology at the University of Maryland School of Medicine. Dr. Moeslein is a member of several organizations, including the Society of Interventional Radiology, the American Medical Association, the American Academy of Sciences, the Radiological Society of North America, Inc., and the Cardiovascular and Interventional Radiological Society of Europe. His research interests including Selective Internal Radiotherapy in the management of both primary and metastatic hepatic malignancies, Image guidance for percutaneous procedures, and novel management strategies for painful bony metastases.

    • Gordon McLennan, MD

      The Cleveland Clinic

      Dr. McLennan received his undergraduate degree from Johns Hopkins University and his medical degree from Virginia Commonwealth University Medical College. Following an internship and residency in general surgery at Mercy Catholic Medical Center in Philadelphia, he completed a Fellowship in Interventional Radiology at the Indiana University Hospital. Dr. McLennan, author of more than 34 published articles, serves as Past Chair of the Society of Interventional Radiology (SIR) Foundation. He is a member of the Board of Trustees of The Renal Network, Inc., and is a member of the Radiological Society of North America, the Society of Interventional Radiology, the Cardiovascular and Interventional Radiology Society of Europe, the American Chemical Society and the Association of University Radiologists. (Dr. McLennan will receive stock options as a member of Surefire's SAB.)

    • John R. Daniels, MD

      USC Norris Comprehensive Cancer Center and Hospital

      John R. Daniels, M.D. is a former chief executive officer and chairman at a number of medical technology companies, as well as an accomplished clinician and past faculty member of the Stanford University School of Medicine. From 1990 to the present, Dr. Daniels has served as an associate professor of medicine in the Division of Oncology at the University of Southern California School Of Medicine. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Daniels has authored more than 100 peer-reviewed articles, book chapter and abstracts for influential medical journals. A graduate of Stanford University’s School of Medicine, Dr. Daniels has been a faculty member at the Keck School of Medicine since 1979.  Dr. Daniels is the founder or co-founder of five start-up companies, including Collagen Corporation (acquired by Inamed), Target Therapeutics (acquired by Boston Scientific Corporation), and Balance Pharmaceuticals.  From 1997 until 2002, Dr. Daniels was Chairman of Cohesion Technologies (acquired by Angiotech Pharmaceuticals). Dr. Daniels holds a B.A. from Stanford University and an M.D. from the Stanford University School of Medicine.

    • Steven Katz, MD, FACS

      Roger Williams Medical Center & Boston University Medical Center

      Dr. Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award for graduating with the top academic average in his class. He completed his general surgery residency at the New York University Medical Center. Dr. Katz completed Fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow.  His clinical expertise is in liver surgery, pancreatic surgery, sarcoma, and melanoma. His laboratory research endeavors focus on immunotherapy for liver metastases and sarcoma.  He was the principal investigator for the Hepatic Immunotherapy for Metastases (HITM) trial, which tested regional infusion of genetically modified T cells for liver metastases. Dr. Katz has received research grants from numerous societies, in addition to an NIH K08 award and an NIH COBRE project. He is a member of numerous professional societies, is a reviewer for numerous scientific and clinical journals, and serves on the editorial boards for the Journal of Surgical Research and Cancer Gene Therapy.

Surefire Products

Surefire
Infusion System mT/ST/LT

Available in three different sizes, the next generation Surefire Infusion System delivers the dose and increases efficiency through a vastly more targeted delivery.

Learn more...

Guiding
Catheters

Surefire’s Guiding Catheters are designed with double-stranded steel braid, an ultra-soft tip and multiple segments.

Learn more...

Specialty
Catheters

With an inner lumen of 0.054”, Surefire’s Specialty Catheters offers a highly trackable and flexible platform for infusion procedures.

Learn more...